Glenmark Pharmaceuticals Ltd (Glenmark) manufactures, develops and markets branded and generic formulations, and OTC products. The company offers branded, generic, and over-the-counter (OTC) products. Glenmark specialises in major therapeutic areas such as respiratory, dermatology, and oncology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Glenmark's R&D endeavours to develop innovative products in the areas of oncology and inflammation disorders, including respiratory and dermatology therapies. The company has a strong pipeline of speciality products and innovative molecules, with a focus on high-quality formulations. The company has been developing branded and generic formulations for over four decades. In January 2024, Glenmark and its subsidiary, Ichnos Sciences Inc., launched the Ichnos Glenmark Innovation alliance to accelerate new drug discovery in cancer treatment. This alliance combines Glenmark's research and development proficiencies in small molecules with those of Ichnos in novel biologics. The newly formed IGI features a broad pipeline of three innovative oncology molecules currently undergoing clinical trials. The company's research and development facilities are located at Mahape, Sinnar, and Taloja. These units are responsible for managing Glenmark's R&D activities, enabling the discovery and development of new therapies. The company has executed 10 out-licensing deals since 2004 and has launched 75 products globally. Major technology alliances include partnerships with BeOne Medicine, Pfizer, 3D Medicines, and Alphamab, which strengthen the company's oncology and dermatology portfolio. 887 Employees in R&D activities. The company is developing innovative therapies, including bispecific and trispecific antibodies for multiple myeloma and solid tumours, as well as monoclonal antibodies for autoimmune diseases. The autoimmune disease assets have been out-licensed to enable a greater focus on oncology. The company collaborates with alliance partners such as Astria Therapeutics and Almirall for the development of specific therapies. A few of its major pipeline products in oncology includes ISB 2001, being developed for the treatment of relapsed/refractory multiple myeloma, is currently in Phase I clinical trials; ISB 1442, for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia, is currently in Phase I clinical trials; and GRC 65327, for the treatment of solid tumors, is in Preclinical stage. The company’s pipeline candidates for autoimmune disease include ISB 880, which is currently in Phase I clinical trials, and ISB 830, being developed for the treatment of atopic dermatitis, is currently in Phase II clinical trials. In FY2025, the company spent INR9,183 million on its R&D activities, which as a percentage of revenue stood at 6.8%.